23 Biomedical Studies Targeting Cancer Imaging, Lutetium-177 Therapy and Precision Medicine

Highlights

• 23 presentations at China's Rare Earth Biomedicine Forum covered Lu-177 radioimmunotherapy, NIR-II imaging, and experimental bone-repair materials.
• Lutetium-177's 6.65-day half-life makes isotope production, radiochemical purification, and rapid distribution the real strategic bottlenecks—not mineral supply alone.
• Medical rare earth applications generate high value from small quantities, shifting China's opportunity toward intellectual property and devices rather than increased tonnage.
• Researchers from Fudan University, Shanghai Jiao Tong University, and the Chinese Academy of Sciences presented work that remains at research stage with no verified clinical outcomes.